cabozantinib

January 23, 2020January 23, 2020

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo

News

Exelixis will expand its Phase 1b clinical trial evaluating a combination of Cabometyx (cabozantinib) with Tecentriq (atezolizumab) to include more patients with metastatic castration-resistant prostate cancer (mCRPC), based on preliminary ... Read more

March 17, 2017March 17, 2017

Immunotherapy Combo Effective in Castration-resistant Prostate Cancer Mouse Models, Study Finds

News

Combining immune checkpoint inhibitors with drugs that target a population of myeloid-derived suppressor cells (MDSCs) may offer hope for men with metastatic prostate cancer who no longer respond to androgen deprivation therapy (ADT). ... Read more

September 10, 2014September 10, 2014

Cometriq Fails to Meet Primary Endpoint in Metastatic Castration-Resistant Prostate Cancer

News

Exelixis, Inc. has announced the results from its COMET-1 phase 3 trial on cabozantinib for the treatment of metastatic castration-resistant prostate cancer (mCRPC) did not meet the primary endpoint of overall ... Read more